Meghan Seago

Meghan Seago

Auto-generated profile, based on publicly available information

Meghan Seago

VA San Diego Healthcare System and University of California San Diego California USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
MSMeghan Seago
Meghan Seago
PSPeter R. Shumaker
Peter R. Shumaker
LSLeah K. Spring
Leah K. Spring
MAMurad Alam
Murad Alam
FAFiras Al‐Niaimi
Firas Al‐Niaimi
JWJill Waibel
Jill Waibel

31 October 2021 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
FSFares Salameh
Fares Salameh
PSPeter R. Shumaker
Peter R. Shumaker
GGGreg J. Goodman
Greg J. Goodman
LSLeah K. Spring
Leah K. Spring
MSMeghan Seago
Meghan Seago
OAOfir Artzi
Ofir Artzi

7 June 2021 in Dermatologic Surgery
Verified
Journal Article
Closed access
MSMeghan Seago
Meghan Seago
AHAnna-Marie Hosking
Anna-Marie Hosking
HGHubert T. Greenway
Hubert T. Greenway
BKBenjamin Kelley
Benjamin Kelley
BACKGROUND: Extraocular sebaceous carcinoma (SC) is rare, with distinct features from its ocular counterpart. These neoplasms have been associated with Muir-Torre syndrome (MTS). Associated internal malignancies include gastrointestinal and genitourinary. OBJECTIVE: Assess for local recurrence, metastasis, disease-specific death, and additional malignancies in patients with extraocular SC treated with Mohs micrographic surgery (MMS) at a single referral center. METHODS: Review of patients with extraocular SC treated with MMS between 1995 and 2019. Follow-up was obtained by chart review. RESULTS: Thirty-eight patients with 41 tumors were identified (25, 66% male). During a mean follow-up of 5.9 ± 5 years, one case of metastasis was identified in an incompletely treated case. No recurrence was identified in the remaining 40 tumors. Five of 41 (12%) tumors had aggressive histologic features. Seven of 38 (18%) patients had a diagnosis of MTS or associated risk factors. There was no association between MTS or its risk factors and high-risk tumors. CONCLUSION: There were no incidences of local recurrence, metastasis, or disease-specific death in cases treated completely with MMS. Metastasis and disease-specific death occurred in an incompletely treated case, highlighting the risk associated with aggressive tumors.